Moneycontrol PRO
Live Now |Traders Carnival 15th Edition - 3 days 12 sessions Virtual Event brought to you by Moneycontrol Pro
you are here: HomeNewsBusiness

Buy Hester Biosciences; target of Rs 2925: ICICI Direct

ICICI Direct is bullish on Hester Biosciences has recommended buy rating on the stock with a target price of Rs 2925 in its research report dated August 13, 2021.

August 19, 2021 / 01:02 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Hester Biosciences

Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzania. It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products Revenue segment wise: poultry healthcare:73%, animal healthcare: 19%, others:8%; by geography: domestic:81%, exports:10%, others:9%


We change our view from HOLD to BUY on account of positive impact of expected improvement in exports We value Hester at Rs 2925 (base business at Rs 2809 i.e. 40x P/E on FY23E EPS + NPV of Rs 114 Covaxin DS opportunity)

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Aug 19, 2021 01:02 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark